B. Lacour and J. Clavel, Aspects épidémiologiques des cancers de l'enfant, Rev Prat, vol.64, issue.9, pp.1264-1273, 2014.

E. Frei, B. A. Teicher, S. A. Holden, K. N. Cathcart, and Y. Y. Wang, Preclinical studies and clinical correlation of the effect of alkylating dose, Cancer Res, vol.48, issue.22, pp.6417-6440, 1988.

M. Czerwinski, J. P. Gibbs, and J. T. Slattery, Busulfan conjugation by glutathione Stransferases alpha, mu, and pi, Drug Metab Dispos Biol Fate Chem, vol.24, issue.9, pp.1015-1024, 1996.

M. Hassan, G. Oberg, H. Ehrsson, M. Ehrnebo, I. Wallin et al.,

, Pharmacokinetic and metabolic studies of high-dose busulphan in adults, Eur J Clin Pharmacol, vol.36, issue.5, pp.525-555, 1989.

B. F. Coles, F. Morel, C. Rauch, W. W. Huber, M. Yang et al., Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression, Pharmacogenetics, vol.11, issue.8, pp.663-672, 2001.

J. Bouligand, I. Boland, D. Valteau-couanet, A. Deroussent, C. Kalifa et al., In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa), Bone Marrow Transplant, vol.32, issue.10, pp.979-86, 2003.

B. Bostrom, K. Enockson, A. Johnson, A. Bruns, and B. Blazar, Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation, Pediatr Transplant, vol.7, issue.3, pp.12-20, 2003.

M. Hassan, G. Oberg, M. Björkholm, I. Wallin, and M. Lindgren, Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics, Cancer Chemother Pharmacol, vol.33, issue.3, pp.181-187, 1993.

M. Hassan, The role of busulfan in bone marrow transplantation, Med Oncol Northwood Lond Engl, vol.16, issue.3, pp.166-76, 1999.

L. B. Grochow, R. J. Jones, R. B. Brundrett, H. G. Braine, T. L. Chen et al., Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation, Cancer Chemother Pharmacol, vol.25, issue.1, pp.55-61, 1989.

G. Vassal, D. Challine, S. Koscielny, O. Hartmann, A. Deroussent et al., Chronopharmacology of high-dose busulfan in children, Cancer Res, vol.53, issue.7, pp.1534-1541, 1993.

L. B. Grochow, W. Krivit, C. B. Whitley, and B. Blazar, Busulfan disposition in children, Blood, vol.75, issue.8, pp.1723-1730, 1990.

M. Hassan, G. Oberg, A. N. Bekassy, J. Aschan, H. Ehrsson et al., Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology, Cancer Chemother Pharmacol, vol.28, issue.2, pp.130-134, 1991.

M. B. Regazzi, F. Locatelli, I. Buggia, F. Bonetti, M. Zecca et al., Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation, Clin Pharmacol Ther, vol.54, issue.1, pp.45-52, 1993.

G. Vassal, A. Deroussent, D. Challine, O. Hartmann, S. Koscielny et al., Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood, vol.79, pp.2475-2484, 1992.

B. S. Andersson, A. Kashyap, V. Gian, J. R. Wingard, H. Fernandez et al., Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.8, issue.3, pp.145-54, 2002.

B. S. Andersson, P. F. Thall, T. Madden, D. Couriel, X. Wang et al., Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.8, issue.9, pp.477-85, 2002.

S. P. Dix, J. R. Wingard, R. E. Mullins, I. Jerkunica, T. G. Davidson et al., Association of busulfan area under the curve with veno-occlusive disease following BMT, Bone Marrow Transplant, vol.17, issue.2, pp.225-255, 1996.

A. M. Bolinger, A. B. Zangwill, J. T. Slattery, L. J. Risler, D. H. Sultan et al., Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation, Bone Marrow Transplant, vol.28, issue.11, pp.1013-1021, 2001.

L. Nguyen, D. Fuller, S. Lennon, F. Leger, and C. I. Puozzo, busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients, Bone Marrow Transplant, vol.33, issue.10, pp.979-87, 2004.

G. Vassal, G. Michel, H. Espérou, J. C. Gentet, D. Valteau-couanet et al., Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring, Cancer Chemother Pharmacol, vol.61, issue.1, pp.113-136, 2008.

G. Michel, D. Valteau-couanet, J. Gentet, H. Esperou, G. Socié et al.,

, Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer, vol.58, pp.90-97, 2012.

S. I. Bearman, The syndrome of hepatic veno-occlusive disease after marrow transplantation, Blood, vol.85, issue.11, pp.3005-3025, 1995.

G. B. Mcdonald, M. S. Hinds, L. D. Fisher, H. G. Schoch, J. L. Wolford et al., Venoocclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients, Ann Intern Med, vol.118, issue.4, pp.255-67, 1993.

J. A. Coppell, P. G. Richardson, R. Soiffer, P. L. Martin, N. A. Kernan et al., Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.16, issue.2, pp.157-68, 2010.

S. I. Bearman, G. L. Anderson, M. Mori, M. S. Hinds, H. M. Shulman et al.,

, Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation, J Clin Oncol Off J Am Soc Clin Oncol, vol.11, issue.9, pp.1729-1765, 1993.

V. Méresse, O. Hartmann, G. Vassal, E. Benhamou, D. Valteau-couanet et al., Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children, Bone Marrow Transplant, vol.10, issue.2, pp.135-176, 1992.

S. Corbacioglu, S. Cesaro, M. Faraci, D. Valteau-couanet, B. Gruhn et al.,

, Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stemcell transplantation: an open-label, phase 3, randomised controlled trial, Lancet Lond Engl, vol.379, issue.9823, pp.1301-1310, 2012.

E. Carreras, H. Bertz, W. Arcese, J. P. Vernant, J. F. Tomás et al., Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party, Blood, vol.92, issue.10, pp.3599-604, 1998.

G. B. Mcdonald, P. Sharma, D. E. Matthews, H. M. Shulman, and E. D. Thomas, Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatol Baltim Md, vol.4, pp.116-138, 1984.

F. L. Dignan, R. F. Wynn, N. Hadzic, J. Karani, A. Quaglia et al., BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation, Br J Haematol, vol.163, issue.4, pp.444-57, 2013.

S. Corbacioglu, M. Hönig, G. Lahr, S. Stöhr, G. Berry et al., Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide, Bone Marrow Transplant, vol.38, issue.8, pp.547-53, 2006.

G. J. Veal, L. Nguyen, A. Paci, M. Riggi, M. Amiel et al., Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving highdose myeloablative chemotherapy for high-risk neuroblastoma as

, Eur J Cancer Oxf Engl, vol.48, issue.16, pp.3063-72, 1990.

M. Ouachée-chardin, C. Elie, G. De-saint-basile, L. Deist, F. Mahlaoui et al., Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a singlecenter report of 48 patients, Pediatrics, vol.117, issue.4, pp.743-750, 2006.

G. B. Mcdonald, Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatol Baltim Md, vol.51, pp.1450-60, 2010.

N. Lassau, A. Auperin, J. Leclere, A. Bennaceur, D. Valteau-couanet et al., Prognostic value of doppler-ultrasonography in hepatic veno-occlusive disease, Transplantation, vol.74, issue.1, pp.60-66, 2002.

R. J. Jones, K. S. Lee, W. E. Beschorner, V. G. Vogel, L. B. Grochow et al.,

, Venoocclusive disease of the liver following bone marrow transplantation, Transplantation, vol.44, issue.6, pp.778-83, 1987.

E. Carreras, A. Grañena, M. Navasa, M. Bruguera, V. Marco et al., On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease, Ann Hematol, vol.66, issue.2, pp.77-80, 1993.

S. Corbacioglu, E. Carreras, M. Ansari, A. Balduzzi, S. Cesaro et al., Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation, Bone Marrow Transplant, vol.53, issue.2, pp.138-183, 2018.

J. H. Essell, M. T. Schroeder, G. S. Harman, R. Halvorson, V. Lew et al., Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, vol.128, issue.12, pp.975-81, 1998.

A. Boucly, B. Girerd, D. Bourlier, S. Nemlaghi, J. Caliez et al.,

, Rev Mal Respir, vol.35, issue.2, pp.160-70, 2018.

D. Heath, N. Segel, and J. Bishop, Pulmonary Veno-Occlusive Disease, Circulation, vol.34, issue.2, pp.242-250, 1966.

F. Schlemmer, S. Chevret, G. Lorillon, D. Bazelaire, C. et al., Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation, Respir Med, vol.108, issue.10, pp.1525-1558, 2014.

F. Patriarca, C. Skert, A. Sperotto, D. Damiani, M. Cerno et al., Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation, Bone Marrow Transplant, vol.33, issue.7, pp.751-759, 2004.

N. Beck, M. Meresse, V. Hartmann, O. Gaultier, and C. , Long-term pulmonary sequelae after autologous bone marrow transplantation in children without total body irradiation, Bone Marrow Transplant, vol.16, issue.6, pp.771-776, 1995.

Y. Lee, R. Huh, J. Kim, K. Ahn, K. W. Sung et al., Late-onset noninfectious interstitial lung disease following autologous haematopoietic stem cell transplantation in paediatric patients, Respirol Carlton Vic, vol.21, issue.6, pp.1068-74, 2016.

D. Valteau, O. Hartmann, E. Benhamou, J. M. Caillaud, L. Brugières et al., Nonbacterial nonfungal interstitial pneumonitis following autologous bone marrow transplantation in children treated with high-dose chemotherapy without total-body irradiation, Transplantation, vol.45, issue.4, pp.737-777, 1988.

G. G. Pietra, F. Capron, S. Stewart, O. Leone, M. Humbert et al., Pathologic assessment of vasculopathies in pulmonary hypertension, J Am Coll Cardiol, vol.43, issue.12, pp.25-32, 2004.

C. A. Wagenvoort and N. Wagenvoort, The pathology of pulmonary veno-occlusive disease, Virchows Arch A Pathol Anat Histol, vol.364, issue.1, pp.69-79, 1974.

D. E. Schraufnagel, M. Sekosan, T. Mcgee, and M. B. Thakkar, Human alveolar capillaries undergo angiogenesis in pulmonary veno-occlusive disease, Eur Respir J, vol.9, issue.2, pp.346-50, 1996.

B. Ranchoux, S. Günther, R. Quarck, M. Chaumais, P. Dorfmüller et al.,

, Chemotherapy-induced pulmonary hypertension: role of alkylating agents, Am J Pathol, vol.185, issue.2, pp.356-71, 2015.

F. Perros, S. Günther, B. Ranchoux, L. Godinas, F. Antigny et al.,

, Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models, Circulation, vol.132, issue.9, pp.834-881, 2015.

D. Montani, E. M. Lau, A. Descatha, X. Jaïs, L. Savale et al., Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease, Eur Respir J, vol.46, issue.6, pp.1721-1752, 2015.

D. Montani, E. M. Lau, P. Dorfmüller, B. Girerd, X. Jaïs et al., Pulmonary venoocclusive disease, Eur Respir J, vol.47, issue.5, pp.1518-1552, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01514453

P. Dorfmüller, D. Montani, and M. Humbert, Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension, Eur Respir J, vol.35, issue.1, pp.6-8, 2010.

P. Dorfmüller, M. Humbert, F. Perros, O. Sanchez, G. Simonneau et al., Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases, Hum Pathol, vol.38, issue.6, pp.893-902, 2007.

S. R. Johnson, D. Patsios, D. M. Hwang, and J. T. Granton, Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension, J Rheumatol, vol.33, issue.11, pp.2347-50, 2006.

X. Troussard, J. F. Bernaudin, C. Cordonnier, J. Fleury, D. Payen et al., Pulmonary veno-occlusive disease after bone marrow transplantation, Thorax, vol.39, issue.12, pp.956-963, 1984.

D. Salzman, D. R. Adkins, F. Craig, C. Freytes, and C. F. Lemaistre, Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review, Bone Marrow Transplant, vol.18, issue.4, pp.755-60, 1996.

M. Seguchi, N. Hirabayashi, Y. Fujii, Y. Azuno, N. Fujita et al., Pulmonary hypertension associated with pulmonary occlusive vasculopathy after allogeneic bone marrow transplantation, Transplantation, vol.69, issue.1, pp.177-186, 2000.

R. C. Hackman, D. K. Madtes, F. B. Petersen, and J. G. Clark, Pulmonary venoocclusive disease following bone marrow transplantation, Transplantation, vol.47, issue.6, pp.989-92, 1989.

N. J. Gloude, S. Jodele, A. Teusink-cross, M. Grimley, S. M. Davies et al., Pulmonary veno-occlusive disease after autologous bone marrow transplant in a child with stage IV neuroblastoma: case report and literature review, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.24, issue.1, pp.405-414, 2003.

D. Montani, L. Achouh, P. Dorfmüller, L. Pavec, J. Sztrymf et al., Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore), vol.87, pp.220-253, 2008.

A. Rabiller, X. Jaïs, A. Hamid, A. Resten, F. Parent et al., Occult alveolar haemorrhage in pulmonary veno-occlusive disease, Eur Respir J, vol.27, issue.1, pp.108-121, 2006.

A. A. Frazier, T. J. Franks, T. Mohammed, I. H. Ozbudak, and J. R. Galvin, From the Archives of the AFIP: pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis, vol.27, pp.867-82, 2007.

A. Resten, S. Maitre, M. Humbert, A. Rabiller, O. Sitbon et al., Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease, AJR Am J Roentgenol, vol.183, issue.1, pp.65-70, 2004.

E. Lau, A. Manes, D. S. Celermajer, and N. Galiè, Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward, Eur Heart J, vol.32, issue.20, pp.2489-98, 2011.

B. W. Holcomb, J. E. Loyd, E. W. Ely, J. Johnson, and I. M. Robbins, Pulmonary veno-occlusive disease: a case series and new observations, Chest, vol.118, issue.6, pp.1671-1680, 2000.

S. M. Palmer, L. J. Robinson, A. Wang, J. R. Gossage, T. Bashore et al., Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary venoocclusive disease, Chest, vol.113, issue.1, pp.237-277, 1998.

N. Galiè, M. Humbert, J. Vachiery, S. Gibbs, I. Lang et al., ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), Eur Respir J, vol.46, issue.4, pp.903-75, 2015.

D. Montani, L. C. Price, P. Dorfmuller, L. Achouh, X. Jaïs et al., Pulmonary venoocclusive disease, Eur Respir J, vol.33, issue.1, pp.189-200, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01514453

J. Mandel, E. J. Mark, and C. A. Hales, Pulmonary veno-occlusive disease, Am J Respir Crit Care Med, vol.162, issue.5, pp.1964-73, 2000.

A. Trotti, R. Byhardt, J. Stetz, C. Gwede, B. Corn et al., Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy, Int J Radiat Oncol Biol Phys, vol.47, issue.1, pp.13-47, 2000.

R. Ladenstein, D. Valteau-couanet, P. Brock, I. Yaniv, V. Castel et al.,

, Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, issue.21, pp.3516-3540, 2010.

D. Valteau-couanet, J. Michon, A. Boneu, C. Rodary, Y. Perel et al., Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.3, pp.532-572, 2005.

C. Coze, O. Hartmann, J. Michon, D. Frappaz, F. Dusol et al., NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology, J Clin Oncol Off J Am Soc Clin Oncol, vol.15, issue.12, pp.3433-3473, 1997.

R. Ladenstein, U. Pötschger, L. Deley, M. C. Whelan, J. Paulussen et al., Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, issue.20, pp.3284-91, 2010.

R. B. Womer, D. C. West, M. D. Krailo, P. S. Dickman, B. R. Pawel et al., Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group, J Clin Oncol, vol.30, issue.33, pp.4148-54, 2012.

G. Bergthold, E. Kababri, M. Varlet, P. Dhermain, F. Sainte-rose et al.,

, High-dose busulfan-thiotepa with autologous stem cell transplantation followed by posterior fossa irradiation in young children with classical or incompletely resected medulloblastoma. Pediatr Blood Cancer, vol.61, pp.907-919, 2014.

J. Grill, C. Sainte-rose, A. Jouvet, J. Gentet, O. Lejars et al., Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children, Lancet Oncol, vol.6, issue.8, pp.573-80, 2005.

M. Stevens, A. Rey, N. Bouvet, C. Ellershaw, J. Sanchez-de-toledo et al., Intensified (6 drug) versus standard (IVA) chemotherapy for high risk non metastatic rhabdomyosarcoma (RMS), J Clin Oncol, vol.95, pp.8515-8515, 2004.

H. P. Mcdowell, A. Foot, C. Ellershaw, D. Machin, C. Giraud et al., Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98, Eur J Cancer Oxf Engl, vol.46, issue.9, pp.1588-95, 1990.

C. Bergeron, P. Thiesse, A. Rey, D. Orbach, P. Boutard et al., Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease, Eur J Cancer Oxf Engl, 1990.

N. Gaspar, B. Occean, H. Pacquement, E. Bompas, C. Bouvier et al., Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study, Eur J Cancer Oxf Engl, vol.88, pp.57-66, 1990.
URL : https://hal.archives-ouvertes.fr/inserm-01667245

C. G. Steward, I. Pellier, A. Mahajan, M. T. Ashworth, A. G. Stuart et al., Severe pulmonary hypertension: a frequent complication of stem cell transplantation for malignant infantile osteopetrosis, Br J Haematol, vol.124, issue.1, pp.63-71, 2004.

J. Höra, Zur Histologie der klinischen "primären Pulmonalsklerose

C. A. Wagenvoort and N. Wagenvoort, The pathology of pulmonary veno-occlusive disease, Virchows Arch A Pathol Anat Histol, vol.364, issue.1, pp.69-79, 1974.

D. Montani, E. M. Lau, P. Dorfmüller, B. Girerd, X. Jaïs et al., Pulmonary venoocclusive disease, Eur Respir J, vol.47, issue.5, pp.1518-1552, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01514453

D. Montani, L. Achouh, P. Dorfmüller, J. L. Pavec, B. Sztrymf et al.,

, Pulmonary Veno-occlusive Disease: Clinical, Functional, Radiologic, and Hemodynamic Characteristics and Outcome of 24 Cases Confirmed by Histology. Medicine (Baltimore), 2008.

, Jul, vol.1, issue.4, pp.220-253

D. Montani, P. Dorfmuller, S. Maitre, X. Jaïs, O. Sitbon et al.,

, Presse Medicale Paris Fr, vol.39, issue.1, pp.134-177, 1983.

E. J. Nossent, F. Antigny, D. Montani, H. J. Bogaard, M. R. Ghigna et al.,

, Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease, J Heart Lung Transplant, vol.37, issue.5, pp.647-55, 2018.

O. Sitbon, L. Savale, X. Jaïs, D. Montani, M. Humbert et al.,

, Presse Medicale Paris Fr, vol.43, issue.9, pp.981-93, 1983.

M. Humbert, S. M. Tre, F. Capron, B. Rain, D. Musset et al., Pulmonary Edema Complicating Continuous Intravenous Prostacyclin in Pulmonary Capillary Hemangiomatosis, Am J Respir Crit Care Med, vol.157, issue.5, pp.1681-1686, 1998.

D. Montani, B. Girerd, X. Jaïs, M. Levy, D. Amar et al., Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study, Lancet Respir Med, vol.5, issue.2, pp.125-159, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01436297

T. Kuroda, H. Hirota, M. Masaki, S. Sugiyama, Y. Oshima et al., Sildenafil as Adjunct Therapy to High-Dose Epoprostenol in a Patient with Pulmonary Veno-Occlusive Disease, Heart Lung Circ, vol.15, issue.2, pp.139-181, 2006.

L. L. Davis, B. Boisblanc, C. E. Glynn, W. R. Summer, and C. Ramirez, Effect of Prostacyclin on Microvascular Pressures in a Patient With Pulmonary Veno-Occlusive Disease, CHEST, vol.108, issue.6, pp.1754-1760, 1995.

D. Montani, X. Jaïs, P. Dorfmuller, G. Simonneau, O. Sitbon et al., Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution, Eur Respir J, vol.34, issue.5, pp.1204-1210, 2009.

M. Eyries, D. Montani, B. Girerd, C. Perret, A. Leroy et al., EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension, Nat Genet, vol.46, issue.1, pp.65-74, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01514453